Literature DB >> 17510409

Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model.

Barbara Fingleton1, Kathy J Carter, Lynn M Matrisian.   

Abstract

Fas ligand (FasL/CD95L), a member of the tumor necrosis factor family, interacts with a specific receptor Fas, ultimately leading to cell death. Tumor expression of FasL has been proposed to aid in immune evasion through a "Fas counterattack" mechanism but has also been described as a proinflammatory factor. Here, we tested the role of FasL in a mouse model of spontaneous tumor development. We used the Min mouse in which multiple benign polyps develop in the intestine due to a mutation in the Apc tumor suppressor gene. Mutant mice deficient in functional FasL, termed gld/gld, were crossed to Min mice to generate tumor-prone animals lacking functional FasL. Comparison of FasL-deficient versus proficient Min mice revealed a significant increase in polyp number in the gld/gld mice. We next assessed immune cell infiltration into adenomas. There was no difference in the number of either lymphocytes or macrophages; however, the number of tumor-infiltrating neutrophils was 3-fold lower in the gld/gld specimens compared with controls. Neutrophil migration in vitro was stimulated by wild-type but not mutant FasL. In a nontumor-bearing colitis model in vivo, neutrophil recruitment to the intestine was also reduced in gld/gld mice. Although the Fas counterattack hypothesis suggests that the absence of FasL would result in increased immune-mediated tumor elimination, the opposite is true in the Min model with lack of functional FasL associated with reduced neutrophil influx and increased tumor development. Thus, the proinflammatory rather than counterattack role of tumor FasL is more relevant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510409     DOI: 10.1158/0008-5472.CAN-06-4473

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance.

Authors:  Mary A Zimmerman; Nur-Taz Rahman; Dafeng Yang; Guy Lahat; Alexander J Lazar; Raphael E Pollock; Dina Lev; Kebin Liu
Journal:  Cancer Res       Date:  2012-07-17       Impact factor: 12.701

2.  Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice.

Authors:  Lisa M Sedger; Arna Katewa; Ann K Pettersen; Sarah R Osvath; Geoff C Farrell; Graeme J Stewart; Linda J Bendall; Stephen I Alexander
Journal:  Blood       Date:  2010-02-25       Impact factor: 22.113

3.  Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.

Authors:  Kebin Liu
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

4.  SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.

Authors:  Chunwan Lu; John D Klement; Dafeng Yang; Thomas Albers; Iryna O Lebedyeva; Jennifer L Waller; Kebin Liu
Journal:  Cancer Lett       Date:  2020-02-12       Impact factor: 8.679

5.  Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.

Authors:  Hector Guillen-Ahlers; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

6.  Effect of P2 receptor on the intracellular calcium increase by cancer cells in human umbilical vein endothelial cells.

Authors:  Namie Nejime; Naoko Tanaka; Ryoko Yoshihara; Satomi Kagota; Noriko Yoshikawa; Kazuki Nakamura; Masaru Kunitomo; Michio Hashimoto; Kazumasa Shinozuka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-22       Impact factor: 3.000

7.  Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.

Authors:  Anton Kuratnik; Virginia E Senapati; Rajeev Verma; Barbara G Mellone; Anthony T Vella; Charles Giardina
Journal:  Biochem Pharmacol       Date:  2012-01-25       Impact factor: 5.858

8.  An apoptosis-independent role of SMAC in tumor suppression.

Authors:  W Qiu; H Liu; A Sebastini; Q Sun; H Wang; L Zhang; J Yu
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 8.756

9.  Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes.

Authors:  Genevieve L Coe; Priscilla S Redd; Amy V Paschall; Chunwan Lu; Lilly Gu; Houjian Cai; Thomas Albers; Iryna O Lebedyeva; Kebin Liu
Journal:  Sci Rep       Date:  2016-08-04       Impact factor: 4.379

Review 10.  Colorectal cancer prevention: Immune modulation taking the stage.

Authors:  Rochelle Fletcher; Yi-Jun Wang; Robert E Schoen; Olivera J Finn; Jian Yu; Lin Zhang
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 11.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.